Trudy from Portugal

Registered at the short selling broker Skilling, 5 minutes ago.

» Try Skilling you too
69% of retail CFD accounts lose money.
Don't show again

Hansa Biopharma AB (HNSBF) shares information

Hansa Biopharma AB

24h Change



Live rate: Market closed

Stock data per Tuesday 29 Jun, 2021

HNSBF (ISIN: SE0002148817)
0 (-%)
US Market is closed

  • Latest Volume


  • Volume prev. day


  • Avg. daily volume


  • Market cap


  • P/E ratio


  • Today high

    18.2 USD

  • Today low


  • 52 week high

    29.5 USD

  • 52 week low

    16.4 USD

  • YTD Change


Quick links


Latest news about Hansa Biopharma AB

Below you can find the most recent news posts about Hansa Biopharma AB, primarily from US and UK based news sources.

Global Guillain-Barre Syndrome Drugs Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: Akari Therapeutics Plc, Hansa Medical AB, Annexon Inc, CuraVac Inc, Vitality Biopharma Inc, Regenesance BV

Saturday, 24 July 2021, 03:37:03
The report on Global Guillain-Barre Syndrome Drugs Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic []
— Jumbo News

Hansa Biopharma AB reports Q2 results

Thursday, 15 July 2021, 11:47:26
No summary available.
— Seeking Alpha

Trading broker recommendation

We recommend that you check out as they have a very good selection of stocks available for both going short and long.

Rating: 9.57/10
Minimum deposit: €250 by bank
Description: offer a large number of stocks for trading. Register an account today and check if they have HNSBF available or trade one of the many other CFD stocks they have.
Risk warning: 67.7% of retail investor accounts lose money when trading CFDs with Capital.